## **The DiaMonD Study**<sup>1</sup>

## Dispelling the Myths of Continuous Glucose Monitoring (CGM) Usage in Patients on Multiple **Daily Injections (MDI)**

The outcomes from the DiaMonD study provides evidence to challenge common misperceptions about CGM\* use in patients on MDI.

\*Study conducted using a previous version of the Dexcom G4® PLATINUM CGM System, which uses the same algorithm as the Dexcom G5® Mobile CGM System.

## **Study Objective & Methods**

24-week prospective, randomised clinical trial of 155 adult patients (> 25 years of age) with Type 1 Diabetes comparing MDI regimen augmented by CGM vs. self-monitoring of blood alucose (SMBG). Primary endpoint was HbA1c reduction in each group. Patient touchpoints reflective of common clinical practice (only one additional follow-up visit for CGM group, one week after CGM was initiated).

## Myth: CGM is too complicated to use.

Results: Patients demonstrated significant HbA1c reductions, regardless of education level, math ability, and age.

